Determinants of quality of life in Latin American people with drug-resistant epilepsy: A cross-sectional, correlational study

Marco Antonio Díaz-Torres^a, Edith Giselle Buzo-Jarquín^a, Aime Carolina Rodríguez-Martínez^b, Diana Laura De León-Altamira^b, Gerardo Padilla-Rivas^c, Sergio Andrés Castillo-Torres^a, Jaime Enrique Giovann Olivas-Reyes^a *, J. Miguel Cisneros-Franco^d *

- ^a Servicio de Neurología, Facultad de Medicina y Hospital Universitario 'Dr. Jose Eleutrio Gonzalez', Universidad Autónoma de Nuevo León, Monterrey, Mexico
- ^b On behalf of 'Grupo de Estudio Contra Enfermedades Neurológicas' (GECEN), Facultad de Medicina y Hospital Universitario 'Dr. Jose Eleutrio Gonzalez', Universidad Autónoma de Nuevo León, Monterrey, Mexico
- ^c Departamento de Biología Molecular, Facultad de Medicina y Hospital Universitario 'Dr. Jose Eleutrio Gonzalez', Universidad Autónoma de Nuevo León, Monterrey, Mexico ^d Integrated Program in Neuroscince, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
- *Address correspondence to:

J. Miguel Cisneros-Franco
Montreal Neurological Institute
753-3801 University
Montreal, QC
H3A 2B4, Canada
mike.cisneros-franco@mail.mcgill.ca

Jaime Enrique Giovann Olivas-Reyes Servicio de Neurologia, Hospital Universitario "Dr. Jose E. Gonzalez". Universidad Autonoma de Nuevo Leon Monterrey, NL, México. CP 64460 giovannreyes@gmail.com

Abstract

2

15

18

19

26

- 3 One third of people with epilepsy (PWE) continue to have seizures despite adequate
- 4 antiepileptic drug treatment. This condition, known as drug-resistant epilepsy (DRE)
- 5 significantly impairs their social, family and work environment. The aims of this study were
- 6 to assess the quality of life (QoL) in PWE with DRE and to investigate which factors are
- 7 associated with a better QoL. This was a cross-sectional observational study of 133 Latin
- 8 American PWE. QoL was assessed with the Spanish version of the Quality of Life with
- 9 Epilepsy questionnaire (QOLIE-10). Independent clinical variables were analyzed with
- 10 non-parametric statistics and their association with QoL was investigated with multiple
- 11 linear regression. Poor quality of life was found in 25.8% of PWE. A low number of
- 12 antiepileptic drugs (AEDs) was the major factor associated with better quality of life.
- 13 closely followed by seizure frequency. We conclude that careful selection of AED
- treatment may contribute to improving both seizure control and QoL.
- 16 Keywords: Epilepsy, Quality of Life, antiepileptic drugs, seizure frequency, drug
- 17 resistance, adverse effects.

Abbreviations

- 20 PWE people with epilepsy
- 21 AED antiepileptic drug
- 22 QoL quality of life
- 23 MH mental health
- 24 DATI daily activities and treatment impact
- 25 QOLIE Quality of Life in Epilepsy questionnaire

Introduction

27

- 28 Epilepsy, one of the most frequent neurological diseases, is defined by the International
- 29 League Against Epilepsy (ILAE) as "the enduring predisposition to suffer epileptic
- 30 seizures" [1]. Drug resistance is found in 30% of people with epilepsy (PWE). This
- 31 condition is associated with significant medical and psychiatric comorbidities, thus
- 32 affecting the patient's social, family and work environment.
- 33 The World Health Organization defines quality of life (QoL) as "the perception that an
- 34 individual has about their position in life and in the context of their culture and value
- 35 system in which they live in relation to their goals, expectations, standards and concerns"
- 36 [2]. However, which factors are the main determinants of QoL in PWE remains unclear.
- 37 Whereas some studies suggest that seizure frequency does not influence quality of life
- 38 [3-5], others have identified drug-resistance as the main predictor of poor QoL [6],
- 39 suggesting that seizure-freedom is necessary for optimal QoL [7-9]. Other studies,
- 40 however, suggest that seizure severity, rather than seizure frequency, is a major
- 41 determinant of QoL [10, 11]. Moreover, studies on the role of AED treatment in QoL have
- 42 not produced consistent results [5, 10, 12].
- We posit that these mixed results might be explained by idiosyncratic factors dependent
- on the specific cohort studied. And although previous studies have measured QoL in Latin
- 45 American PWE [13–15], the specific determinants of QoL in patients with DRE remain
- 46 understudied. To address this gap in knowledge, we set to study QoL in the outpatient
- 47 clinic of our institution, a tertiary referral center with an overrepresentation of patients with
- 48 DRE.

49

Material and methods

- 50 Patients and study design
- 51 This was a cross-sectional and observational study of 133 consecutive s PWE evaluated
- 52 between the years 2016 and 2018, in the outpatient clinic of a tertiary academic center.
- 53 The study included adult patients diagnosed with epilepsy for at least one year and
- 54 according to the ILAE epilepsy diagnostic criteria [1]. Individuals with intellectual
- 55 impairment, diseases that prevent the individual from understanding the questionnaire,
- those with a history of head trauma with massive bleeding, subjects with severe systemic
- 57 diseases, non-epileptic seizures, and individuals with uncertain diagnosis or an
- 58 incomplete medical record were excluded.
- 59 Clinical data, including classification of epilepsy, seizure type, seizure frequency, AED
- 60 use, AED-associated adverse effects, etiology, age of epilepsy onset, and a depression

- 61 diagnosis were obtained from the medical record. All patients were interviewed by a
- trained epileptologist, who verified the inclusion and exclusion criteria. The specialist also
- confirmed the diagnosis of epilepsy, detected cases of drug-resistant epilepsy according
- to ILAE criteria [16], and corroborated the syndromic diagnosis of each case. The clinical
- and demographic information was deposited in an institutional computer database for
- 66 subsequent analysis.
- 67 QoL assessment
- The Quality of Life in Epilepsy-10 (QOLIE-10), Spanish version [17] was administered by
- a psychologist with experience in the field of neurology. The test comprises ten items
- 70 rated from 1 to 5. It evaluates two components,; namely, Factor of Daily Activities and
- 71 Impact of Treatment (DAIT, driving, social function, work, mental, physical and memory
- 72 effects and mental health (overall score of quality of life, depression data, and the
- energy/fatigue ratio.) These values are given a score between 0 and 100, where 91–100
- is excellent quality of life; 81–90 is very good; 71–80, good; 61–70, regular; and <60 poor.
- 75 The research subjects were grouped according to clinical and sociodemographic
- variables in order to compare the scores obtained in each component of the QOLIE-10:
- 77 overall QoL, mental health, and DAIT.
- 78 Statistical analysis
- 79 Analysis was done with SPSS version 23 (IBM). Normality was assessed with the
- 80 Kolmogorov-Smirnov test. For continuous parametric variables, the mean is reported.
- 81 Non-parametric variables regressed with clinical variables. Student's t-test was used for
- 82 parametric data, whereas Mann Whitney-U test and Kruskal-Wallis test were used for
- 83 nonparametric data. Statistically significant variables (p < 0.05) were included in a linear
- 84 regression model.

Results

86 Participants

- A total of 133 individuals were included. The population was composed mainly of single
- 88 individuals in their third decade of life with a basic education, and with focal and structural
- 89 drug-resistant epilepsy (Table 1).
- 90 Valproate was the most widely used AED in polytherapy (42.5%) as well as in
- 91 monotherapy (33.1%). Adverse drug events occurred in 34.5% of cases; the majority
- 92 were non-serious adverse effects such weight gain or weight loss (17.4%, n = 23), mood

- alterations, 6.1% (n = 8), and drowsiness and occasional dizziness in 5.3% (n = 7). Other
- 94 clinical and sociodemographic characteristics are summarized in Table 1.
- 95 Median (P50) total QOLIE score was 77.5 with an interquartile range of 60-87.5 and a
- 96 range of 37.5–87.5 (Table 2).
- 97 A majority of participants reported good, very good or excellent quality of life (62.4%, n =
- 98 83). Similarly, 66.9% of participants showed good, very good or excellent quality in
- 99 activities of daily life and impact of antiepileptic treatment. In contrast, mental health was
- reported as "poor" in one third of our population (33.8%) (Table 3).
- 101 Determinants of quality of life
- 102 To assess the relationship between QoL and a range of clinical and demographic
- variables, we compared QOLIE-10 scores between sub-groups of PWE determined as a
- 104 function of these variables (Table 3).
- 105 Regarding pharmacological therapy, we found a significant difference in QoL as a function
- of the number of drugs used. In this population, those patients who used three or more
- antiepileptic drugs had lower overall QOLIE scores (median score: 1 AED, 82.5; 2 AEDs,
- 108 72.5; 3 or more AEDs, 62.5; p = .002; Table 3).
- 109 Patients medicated with three or more AEDs also had lower scores in the mental health
- 110 component (MH median: 1 AED, 68.7; 2 AEDs, 62.5; 3 or more AEDs, 50; p = .002) and
- also in the component that evaluates daily activities and treatment impact (DATI median:
- 112 1 AED, 87.5; 2 AEDs, 75; 3 or more AEDs, 66.6; p = .055). Moreover, patients with slight
- adverse drug effects had lower daily activities and treatment impact scores (DATI median:
- with AE, 62.5; without AE, 68.7; p = .011), which were reflected as a worse overall quality
- of life (median QoL: with AE, 72.5; without AE, 80; p = 0.017) (Table 3).
- We found no significant effect of the number or AEDs used on QoL sub-scores or in
- overall QoL. Nevertheless, we noted a trend whereby patients treated with more than two
- 118 AEDs had lower overall QoL scores, regardless of the specific drugs used (MH median
- 119 50, p = .036; Table 3).
- 120 Patients with the highest number of seizures per year had lower scores in all of the QoL
- 121 components (QL, p = .005; MH, p = .022; DATI, p = .026). Finally, no significant difference
- was found in QoL scores between patients with or without depression (28.4% and 31.6%,
- 123 respectively).
- 124 Linear regression
- Building on the previous results, we included the variables number of seizures, number

- of current AEDs, and the variables listed in Table 4 in a linear regression model. We found
- that both seizure frequency (p = .010) and the number of current AEDs (p = .008) were
- 128 significantly correlated with overall QoL. The beta coefficients indicated that both
- variables were inversely correlated with QoL, such that a greater number of drugs or
- 130 greater seizure frequency were associated with greater work and social limitations,
- memory impairment, and lower MH scores (Table 4).
- Finally, no significant differences were found in QoL as a function of sociodemographic
- factors such as gender, age, and educational level. Likewise, there were no significant
- 134 differences in QoL as a function of clinical variables such as epilepsy type (focal vs.
- 135 generalized epilepsy), time of evolution, seizure type, specific AED used (in case of
- monotherapy), type of epileptic syndromes, topographic diagnosis, etiology, and the
- 137 presence of depression (Table 5).

Discussion

- 139 Overall quality of life in drug-resistant epilepsy.
- Our work extends previous reports on PWE that, despite assessing QoL in different types
- of epilepsy, did not specifically study the effect of or made a distinction between the
- different degrees of control of each patient. In general, we found few impediments in daily
- activities and few social limitations despite the presence of drug-resistant epikepsy. QoL
- was good or excellent in 62.4% of cases. These results are at odds with two previous
- 145 studies in Latin American PWE without DRE [15, 18]. These studies reported a higher
- proportion (43.3% and 31%, respectively) of PWE with a poor QoL (score < 60), relative
- to the present investigation (25.6%). However, in the perception of mental-emotional
- health we found similarities in comparison to other studies [18] where one third of patients
- stated difficulties in memory, energy, and low mood.
- 150 Seizure frequency and pharmacological therapy
- Multiple previous studies have concluded that, unless seizure freedom is achieved [7–9,
- 152 19], seizure frequency does not have a significant impact on quality of life [4, 5, 11, 20].
- Our results, however, suggest that seizure frequency is a major determinant of QoL in
- people with DRE, as previously reported in studies in which individuals with higher seizure
- 155 frequency exhibited a poorer quality of life [6, 14]. Although it was not possible to achieve
- 156 complete control of seizures in patients with DRE, individuals with a lower seizure
- 157 frequency had a better quality of life. These findings are in good agreement with previous
- studies in PWE with partial or total response to AED therapy [19–22] (but see [23]).
- 159 Antiepileptic therapy was another determinant factor of overall QoL, suggesting that, in

- terms of AEDs, "more does not always mean better". Notably, our results suggest that, even in patients on polytherapy, fewer AEDs are associated with a better QoL [14].
- The relationship between AED side effects of antiepileptic treatment and a poorer quality of life might be explained by two factors. First, impaired cognition associated with AED use may directly impact social interactions and other activities of daily life. Second, drug adverse effects may also potentiate the negative impact on quality of life caused by mood disorders (e.g., depression) and anxiety [21]. We therefore posit that an individualized approach, with special consideration on optimizing AED use, might translate into better
- social functioning, memory, and mood outcomes.
- 169 We theorize that antiepileptic polytherapy impairs the quality of life of patients by affecting 170 social and functional aspects but also by concentration and memory impairments that 171 affect the mental and emotional health of the individual and increasing the presence of 172 side effects that considerably limit the functionality of the individual and his or her daily 173 activities. Although this was not significant in this study, there is a possibility that the mere 174 perception of adverse pharmacological effects could represent sufficient burden to impair 175 quality of life [24]. In patients on polytherapy, determining which treatments are 176 associated with better QoL outcomes represents a challenge, due to the existence of 177 multiple combinations of AEDs.
 - It should be noted that the effect of AEDs on quality of life might be at least partially independent from that caused by the persistence of seizures. Although a greater number of drugs are often used in cases of patients with a greater number of seizures, these two factors may be considered independently. On the one hand a high frequency of seizures mainly affects independence and social function, increases the worry of suffering injuries and falls during seizures, and consequently affects quality of life [19–22]. On the other hand, the number of drugs might influence quality of life through adverse effects and drug interactions resulting from polypharmacy. This is consistent with studies such as those conducted by Auriel et al. [25] and Zou et al. [26], which single out adverse drug effects as the most important factor for quality of life in patients with freedom from seizures and who have suspended medication.

Depression

178

179

180

181

182

183

184

185

186

187

188

- Unlike studies by (Akdemir et al., 2016) and (Espinosa Jovel et al., 2016) that established a negative association between low quality of life, depression and etiology, we did not find significant differences in quality of life among patients with depression, nor between epilepsy of unknown, structural, and genetic etiology. However, in our study, the presence or absence of depression was determined from the clinical record and no depression screening scale was applied. Because of this there is a possibility that depression has
- 196 been underdiagnosed.

Limitations of the study

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

219

The study was conducted in a tertiary care academic hospital that provides health services to the patients across five neighboring states, most of which belong to low and middle socioeconomic status and who do not have access to other institutional medical services. For this reason, a significant proportion of our outpatient population consists of referred individuals with inadequate seizure control. Although the cost of medical visits for most patients (67.9% in our sample) is covered by the public health system, medications are not available on-site. For this reason, patients, or their relatives, must go to other institutions to fill their prescriptions. On a related note, the range of AEDs available through public drug insurance is limited to carbamazepine, phenobarbital, phenytoin and valproate. As a result, these drugs are widely used in our population even though there are better options with fewer side effects. Epilepsy surgery, although available in our region, is not covered by the public health system, thus making it more difficult to address drug resistance.

Recommendations for future studies

- 212 Studies that plan to study the quality of life of patients with epilepsy should consider the
- 213 role of psychiatric comorbidities such as anxiety and depression. These conditions are
- 214 more frequent in patients with epilepsy and are related to a poor quality of life [4, 12, 27,
- 215 28]. However, as these diagnoses may be underreported in health records [4, 29, 30], we
- 216 suggest the inclusion of a screening tool to detect these and other comorbidities.
- 217 Subsequent studies should consider the perception that the individual has about their
- 218 condition and how it relates to their social environment and health system [31].

Conclusions

- 220 Despite mounting evidence that DRE has deleterious effects on multiple aspects of life in
- 221 PWE, the practice of focusing solely on addressing seizure frequency and severity
- remains deeply rooted in current clinical practice. However, it is necessary to carefully
- 223 choose the medication that will be most likely to achieve the dual goal of reducing seizure
- frequency with the fewest possible side effects.
- In adequately selected cases of DRE, epilepsy surgery represents the best intervention
- 226 to achieve freedom from seizures and AEDs, alongside improved quality of life [32].
- 227 However, this and other invasive therapy options remain unattainable for most drug-
- 228 resistant patients in our clinical setting due to resource scarcity. This situation poses a
- 229 dilemma in current clinical practice, because in order to improve QoL it is important to
- 230 reduce the number of seizures; however, the addition of a second or even a third
- 231 antiepileptic drug can negatively influence both the patient's mental health and daily

- 232 activities, resulting in a poor quality of life. Non-pharmacological therapies, including
- 233 patient support groups, screening for anxiety and depression [33, 34], and counseling
- 234 need to be offered as early as possible to improve social function and overall quality of
- 235 life.

236

241

251

252

Financial disclosure

- This research did not receive any specific funding from public, commercial or not-for-profit
- 238 agencies.

239 Conflicts of interest

240 The authors declare that they have no conflicts of interest.

Author contributions

- 242 Conceptualization: M.A.D.-T.; Formal analysis: M.A.D.-T., J.E.G.O.-R., G.P.-R., E.G.B.-
- 243 J.; Investigation: M.A.D.-T., J.E.G.O.-R., E.G.B.-J., A.C.R.-M., D.L.d.L.-A.; Project
- administration: M.A.D.-T., J.E.G.O.-R., A.C.R.-M., D.L.d.L.-A.; Supervision: M.A.D.-T.;
- Visualization: J.E.G.O.-R., G.P.-R.; Writing original draft: J.E.G.O.-R., S.A.C.-T.; Writing
- 246 review & editing: M.A.D.-T., S.A.C.-T., G.P.-R., J.M.C.-F.

247 Acknowledgements

- 248 The database for this study was created by Engineer José Luis González-Garza. Data
- entry was done in part by the Study Group Against Neurological Diseases (GECEN),
- 250 Universidad Autónoma de Nuevo León School of Medicine (Monterrey, Mexico).

References

- Fisher RS, Acevedo C, Arzimanoglou A, et al (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482
- 255 2. WHO (1993) Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 2:153–159
- 257 3. Choi-Kwon S, Chung C, Kim H, et al (2003) Factors affecting the quality of life in patients with epilepsy in Seoul, South Korea. Acta Neurol Scand 108:428–434
- 259 4. Boylan LS, Flint LA, Labovitz DL, et al (2004) Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 62:258–261

- Chen Y-Y, Huang S, Wu W-Y, et al (2018) Associated and predictive factors of quality of
 life in patients with temporal lobe epilepsy. Epilepsy Behav 86:85–90
- 6. Guekht AB, Mitrokhina TV, Lebedeva AV, et al (2007) Factors influencing on quality of life in people with epilepsy. Seizure 16:128–133
- 7. Birbeck GL, Hays RD, Cui X, Vickrey BG (2002) Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43:535–538
- 267 8. Jacoby A, Snape D, Baker GA (2009) Determinants of quality of life in people with epilepsy.
 268 Neurol Clin 27:843–863
- 269 9. Kanner AM, Barry JJ, Gilliam F, et al (2010) Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy? Epilepsia 51:1152–1158
- 272 10. Elliott JO, Richardson VE (2014) The biopsychosocial model and quality of life in persons
 273 with active epilepsy. Epilepsy Behav 41:55–65
- 11. Vickrey BG, Berg AT, Sperling MR, et al (2000) Relationships between seizure severity and
 health-related quality of life in refractory localization-related epilepsy. Epilepsia 41:760–764
- 276 12. Milovanović M, Martinović Ž, Tošković O (2014) Determinants of quality of life in people with epilepsy in Serbia. Epilepsy Behav 31:160–166
- Alonso-Vanegas MA, Cisneros-Franco JM, Castillo-Montoya C, et al (2013) Self-reported
 quality of life in pharmacoresistant temporal lobe epilepsy: correlation with clinical variables
 and memory evaluation. Epileptic Disord 15:263–271
- 281 14. Camara-Lemarroy CR, Hoyos M, Ibarra-Yruegas BE, et al (2017) Affective symptoms and determinants of health-related quality of life in Mexican people with epilepsy. Neurol Sci 38:1829–1834
- 284 15. Palacios E, Vicuña M, Pulido AC, Vergara JP (2015) Calidad de vida en pacientes con 285 epilepsia que son atendidos en el departamento de neurología del Hospital San José de 286 Bogotá. Acta Neurológica Colombiana 31:235–239
- 287 16. Kwan P, Arzimanoglou A, Berg AT, et al (2010) Definition of drug resistant epilepsy:
 288 consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic
 289 Strategies. Epilepsia 51:1069–1077
- 290 17. Viteri C, Codina M, Cobaleda S, et al (2008) [Validation of the Spanish version of the QOLIE-10 quality of life in epilepsy questionnaire]. Neurologia 23:157–167
- 292 18. Rossinol A, Molina I, Rossinol T, Garcia-Mas A (2013) [Quality of life and perceived general health state related to seizure type and frequency, electroencephalographic findings, cognitive impairment, therapeutic response and secondary effects in persons with epilepsy]. Rev Neurol 57:17–24
- 296 19. Park S-P, Song H-S, Hwang Y-H, et al (2010) Differential effects of seizure control and affective symptoms on quality of life in people with epilepsy. Epilepsy Behav 18:455–459
- 298 20. Chen H-F, Tsai Y-F, Hsi M-S, Chen J-C (2016) Factors affecting quality of life in adults with

- epilepsy in Taiwan: A cross-sectional, correlational study. Epilepsy Behay 58:26–32
- 21. Lee S-J, Kim J-E, Seo J-G, et al (2014) Predictors of quality of life and their interrelations in Korean people with epilepsy: a MEPSY study. Seizure 23:762–768
- 302 22. Velez FF, Bond TC, Anastassopoulos KP, et al (2017) Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-
- onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate.
- 305 Epilepsy Behav 68:203–207
- 306 23. Alexander HB, Broshek DK, Quigg M (2018) Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status. Epilepsy 308 Behav 78:96–99
- 309 24. Yue L, Yu P-M, Zhao D-H, et al (2011) Determinants of quality of life in people with epilepsy 310 and their gender differences. Epilepsy Behav 22:692–696
- 311 25. Auriel E, Landov H, Blatt I, et al (2009) Quality of life in seizure-free patients with epilepsy 312 on monotherapy. Epilepsy Behav 14:130–133
- 26. Zou X, Hong Z, Chen J, Zhou D (2014) Is antiepileptic drug withdrawal status related to quality of life in seizure-free adult patients with epilepsy? Epilepsy Behav 31:129–135
- 27. Espinosa Jovel CA, Ramírez Salazar S, Rincón Rodríguez C, Sobrino Mejía FE (2016)
 Factors associated with quality of life in a low-income population with epilepsy. Epilepsy

317 Res 127:168–174

- 318 28. Akdemir V, Sut N, Guldiken B (2016) Factors affecting the quality of life in drug-resistant epilepsy patients. Acta Neurol Belg 116:513–518
- 320 29. Garcia ME, Garcia-Morales I, Gil-Nagel A (2015) Prevalence of depressive symptoms and their impact on quality of life in patients with drug-resistant focal epilepsy (IMDYVA study). 322 Epilepsy Res 110:157–165
- 323 30. Cisneros-Franco JM, Díaz-Torres MA, Rodríguez-Castañeda JB, et al (2013) Impact of the implementation of the AAN epilepsy quality measures on the medical records in a university hospital. BMC Neurol 13:112
- 31. Sarudiansky M, Korman GP, Scévola L, et al (2018) A life with seizures: Argentine patients' perspectives about the impact of drug-resistant epilepsy on their lives. Seizure 63:52–61
- 32. Liu J-T, Liu B, Zhang H (2018) Surgical versus medical treatment of drug-resistant epilepsy: 329 A systematic review and meta-analysis. Epilepsy Behav 82:179–188
- 33. Cano-López I, Hampel KG, Garcés M, et al (2018) Quality of life in drug-resistant epilepsy:
 relationships with negative affectivity, memory, somatic symptoms and social support. J
 Psychosom Res 114:31–37
- 333 34. Mula M, Cock HR (2015) More than seizures: improving the lives of people with refractory epilepsy. Eur J Neurol 22:24–30

Table 1 Clinical and demographic data

336

				337
TOTAL: 133				338
		median	SD	330
Age (y)		34.3	13.5	339
Age at epilepsy onset		16.1	18.4	339
(y)				240
Disease duration		18.6	16	340
				341
		n=	%	341
Sex	Male	54	59.4	242
	Female	79	40.6	342
Marital status	Single	80	59.8	242
	Married	27	20.3	343
	Separated	13	9.8	244
	De facto	13	9.8	344
	spouse			
Educationlevel	Literate	7	5.3	
	Grades 1-6	29	21.8	
	Grades 7-9	53	39.8	
	Grades 10-12	34	25.6	
	University	10	7.5	
Typeofepilepsy	Focal	106	20.3	
	Generalized	27	79.7	
AED	Polytherapy	52	39.1	
	Monotherapy	81	60.9.	
Etiology	Unknown	41	30.8	
. ,	Structural	71	53.4	
	Genetic	21	15.8	
Specific epileptic	JME	16	12.1	
syndromes				
-	MTLE-HS ³	18	13.6	

AED: antiepileptic drug

JME: juvenile myoclonic epilepsy

MTLE-HS: medial temporal lobe epilepsy with hippocampal sclerosis

Table 2 QOLIE-10 results

Escalas	Poor n (%)	Regular n (%)	Good n (%)	Verygood n (%)	Excellent n (%)
Mental Health	45 (33.7)	36 (27.2)	16 (12)	27 (20.3)	9 (6.8)
Activities of	20 (21.8)	15 (11.3)	13 (9.8)	25 (18.8)	51 (38.3)
dailylife					
QoL	34 (25.6)	16 (12)	32 (24.1)	33 (24.8)	18 (13.5)

Table 3 Differences in QoLfor PWE subgroups

	Mental Health Percentile 50	P25-P75	р	Activities of daily life P50	P25- P75		QoL P50	P25- P75	p
Treatment Monotherapy a (n=81)	68.7	56.2- 81.2	N S	87.5	66.6- 95.8	.00 3	80	66- 87.5	.00 4
Polytherapy ^a (n=52)	62.5	50-75		75	58.3- 91.6		72.5	57.5- 80	
Adverse effects									
Withouta	68.7	(56-81)	N	87.5	(70.8-	.01	80	(66.6-	.01
(n=87) With ^a (n=46)	62.5	(50-81)	S	77	95.8) (58- 87.5)	1	72.5	87.5) (57.5- 80)	7
Number of AEDs									
1 ^b (n=81)	68.7	56.2- 81.2	.0 02	87.500	72.9- 95.8	.05 5	82.5	67.5- 87.5	.00
2 ^b (n=41)	62.5	50-75.		75.000	59.1- 87.5		72.5	56.2- 78.7	
3 ^b (n=11)	50.0	37.5- 81.2		66.667	50-83.3		62.5	50- 77.5	
Seizure frequency									
0 ^b (n=21)	75	62.5- 87.5	.0 17	95.8	85.4- 100	.01 6	86.1	76.2- 93.7	.00 2
1-3 ^b (n=27)	75	62.5- 81.2		87.5	70.8- 95.8		80.5	70-90	
4-6 ^b (n=24)	62.5	51.5-75		82.0	55.2- 94.7		73.7	53.7- 87.5	
6-12 b (n=31)	62.5	50-75		75.0	58.3- 87.5		70.0	50- 77.5	
>12 b (n=30)	62.5	50-71.8		75.0	59.1- 91.6		72.5	57.9- 81.2	

AED: antiepileptic drug

352

a- Mann-Whitney test

b- Kruskal-Wallis test

NS: not statistically significant

Table 4 Multivariate regression of QoL determinants

Score and variables	Standardized B Coefficient	sig	R ² adjusted	95% CI (lower, u	pperlimits)	Standardized B Coefficient	sig.	R ² adjusted	95% CI (lower, upp	erlimits)
	1st regression					2nd regression Without non-significant variables				
QoL										
Adverse effects	-3.412	N S	.098					.109		
Seizure frequency	-3.253	.0 07		- 5.109	575	-2.872	.01 0		-4.973	614
Number of AEDs	-5.951	.0 18		- 10.27	277	-6.363	.00 8		-11.66	-1.632
Marital	.720	N S								
status										
Education	1.495	N S								
Age at epilepsy onset	100	N S								
Etiology	-1.453	N S								
Depression	3.892	N S								
Mental Health										
Seizure frequency						-2.840	.00 9	.097	-4.814	670
Number of						-5.278	.02 3		-9.843	740
AEDs										
Daily-life activities										
Seizure						-2.736	.05 0	.078	-5.414	.031
frequency										
Number of						-7.459	.01 3		-13.322	-1.538
AEDs	tically significan									<u> </u>

355

Table 5. Variables not significantly associated with QoL (p-values)

Scales	Mental Health	Daily-lifeactivities	QoL				
Age ^a	.661	.663	.468				
Sex ^b	.138	.744	.554				
Educationa	.209	.670	.557				
Age at epilepsy onset ^a	.861	.721	.803				
Duration of disease ^a	.174	.256	.217				
Epilepsy type ^b	.456	.656	.622				
Seizure type ^a	.691	.128	.298				
Etiologya	.314	.622	.341				
Syndromic diagnosis ^b	.482	.551	.422				
Topographic diagnosisa	.212	.783	.569				
Depression ^b	.873	.839	.795				
a-Kruskal-Wallis test b-Mann Whitney test							